Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Bleomycin; Doxorubicin; Etoposide; Liposomal doxorubicin; Mechlorethamine; Prednisone; Vinblastine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed Hodgkin's lymphoma of any histology

• Unfavorable disease required

• Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)

• Locally extensive stage I or II with either of the following:

• Mediastinal mass greater than 1/3 the maximum intrathoracic diameter

• Two or more extranodal sites

PATIENT CHARACTERISTICS:

Age:

• 18 to 60

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No prior malignancy except nonmelanomatous skin cancer

• No significant concurrent illness that precludes protocol participation

PRIOR CONCURRENT THERAPY:

• No prior treatment for Hodgkin's lymphoma

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified